Aerpio Pharmaceuticals reported a second quarter net loss of $5.7 million, or $0.14 per share, compared with a net loss of $6 million, or $0.22 per share, in the same period a year ago, according to a press release.
Research and development expenses decreased from $4.2 million in second quarter 2018 to approximately $2.3 million in second quarter 2019, which was attributed to decreased expenses associated with the TIME-2b clinical trial of AKB-9778.
General and administrative expenses decreased to $2.8 million compared with $3.1 million in the same period a (Read more...)
Uncategorized